Circulating tumor cells in the diagnosis and treatment of early and advanced prostate cancer.
- Author:
Yan-Yuan WU
1
;
Jie DING
1
;
Qiang BAI
1
;
Jun QI
1
Author Information
1. Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200001, China.
- Publication Type:Review
- Keywords:
circulating tumor cell;
individualized therapy;
neoplasm metastasis;
prostate cancer
- MeSH:
Cell Count;
Humans;
Male;
Neoplasms, Second Primary;
Neoplastic Cells, Circulating;
Prognosis;
Prostatic Neoplasms/therapy*
- From:
National Journal of Andrology
2021;27(10):934-940
- CountryChina
- Language:Chinese
-
Abstract:
Circulating tumor cells (CTC) are tumor cells that escape from the primary or metastatic tumor into the circulatory system, and closely related to cancer metastasis. Since the samples can be obtained through simple and minimally invasive blood sampling operations, CTCs have a great clinical potential. PCa is one of the most common malignant tumors in men. In recent years, many scholars have conducted studies as to whether CTC technology can be used for the diagnosis and treatment of PCa, as well as for more accurate prediction of the risk of progression. This article summarizes the advances in researches relating CTC technology and the diagnosis and treatment of PCa. CTC detection has been developed from simple counting to phenotypic classification, and even to its combination with the determination of the expressions of specific genes (such as AR, AR-V7, etc.) and single-cell sequencing. Some reports showed that CTC technology has a certain significance in the early diagnosis of PCa, but its main value is demonstrated in drug sensitivity and prognosis evaluation in the late stage of the malignancy. The standardized detection methods and reference values of CTCs in PCa will be important research orientations in the near future.
